Clinical studies of aztreonam in Japan.
Clinical studies of aztreonam were undertaken by 220 investigators in 86 university and general hospitals in Japan. A total of 1,447 patients were treated by investigators in various fields. Satisfactory clinical responses were achieved in 67% of all patients. Efficacy rates by field of specialty were: internal medicine, 67%; urology, 61%; general surgery, 73%; and surgical patients in other fields (obstetrics-gynecology, otorhinolaryngology, and ophthalmology), 78%. Among 364 patients with complicated urinary tract infections, the efficacy rate was 60%. Seventy-four percent of 1,122 gram-negative aerobic organisms were eradicated after treatment with aztreonam. Adverse reactions occurred in 2.1% of patients; none were serious. Mild elevations of serum aminotransferases were observed in approximately 4% of patients for whom test results were reported. In conclusion, aztreonam demonstrated remarkable effectiveness in the treatment of gram-negative infections in hospitalized patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001398:Aztreonam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006088:Gram-Negative Aerobic Bacteria / Q000302:isolation & purification; D006801:Humans; D007564:Japan; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy
D001398:Aztreonam